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C13ORF18 is frequently hypermethylated in cervical cancer but not in normal 
cervix and might serve as a biomarker for the early detection of cervical cancer in 
scrapings. As hypermethylation is often observed for silenced tumor suppressor 
genes (TSGs), hypermethylated biomarker genes might exhibit tumor suppressive 
activities upon re-expression. Epigenetic drugs are successfully exploited to 
reverse TSG silencing, but act genome-wide. Artificial Transcription Factors (ATFs) 
provide a gene-specific approach for re-expression of silenced genes. Here, we 
investigated the potential tumor suppressive role of C13ORF18 in cervical cancer 
by ATF-induced re-expression. 
Five zinc finger proteins were engineered to bind the C13ORF18 promoter and 
fused to a strong transcriptional activator. C13ORF18 expression could be induced 
in cervical cell lines: ranging from >40-fold in positive (C13ORF18-unmethylated) 
cells to >110-fold in negative (C13ORF18-methylated) cells. Re-activation of 
C13ORF18 resulted in significant cell growth inhibition and/or induction of 
apoptosis. Co-treatment of cell lines with ATFs and epigenetic drugs further 
enhanced the ATF-induced effects. Interestingly, re-activation of C13ORF18 led to 
partial demethylation of the C13ORF18 promoter and decreased repressive 
histone methylation. These data demonstrate the potency of ATFs to re-express 
and potentially demethylate hypermethylated silenced genes. Concluding, we 
show that C13ORF18 has a TSG function in cervical cancer and may serve as a 
therapeutic anti-cancer target. As the amount of epimutations in cancer exceeds 
the number of gene mutations, ATFs provide promising tools to validate 






















Aberrant epigenetic regulation, including promoter hypermethylation of tumor 
suppressor genes (TSGs), is a significant event in the progression of cancer (1). In 
the last decade, genome-wide mapping of DNA methylation in normal and cancer 
genomes revealed that a large number of genes is associated with 
hypermethylated CpG islands in cancer; these epimutations exceed by far the 
number of genetic mutated genes (1, 2). Genes specifically hypermethylated in 
cancer might provide diagnostic biomarkers, and the number of such methylated 
markers has increased dramatically in the last years (3-5). A therapeutic 
application of such epigenetically silenced marker genes lies in the fact that they 
might exhibit tumor suppressive activities upon re-expression. Indeed, re-
introduction of single genes into cancer cells where the gene is inactivated, such 
as CDKN2A (encoding p16Ink4A) or TP53, showed potent anti-tumor effects (6, 7). 
However, the therapeutic efficacy of gene transfer in patients still faces significant 
challenges (8). 
      Contrary to genes that are inactivated through genetic mutations, epigenetic 
deregulation is a reversible process and can be targeted by epigenetic drugs that 
affect DNA methylation and histone modification. Current clinical drugs affecting 
epimutations, such as the DNA methylation inhibitor 5-aza-deoxyCytosine (5-aza-
dC) and the histone deacetylase inhibitor suberoylanilide hydroxamic acid, indeed 
induce re-expression of a variety of hypermethylated silenced genes (9). So far, 
four epigenetic drugs have been FDA approved for subtypes of leukemias and 
lymphomas, and ongoing clinical trials in solid tumors indicate some beneficial 
effects for these patients as well (10). However, the disadvantages of these drugs 
include their lack of gene-target specificity (11). In that respect it is important to 
note that epigenetic drugs have been shown to drive tumor promotion and 
metastasis by enhanced expression of off-target genes (12). Similarly, epigenetic 
drugs might also upregulate drug-resistance genes, again causingunwanted side 
effects. Therefore, there is clearly a need for gene targeted re-expression (5). 
     To exploit reversibility of epigenetic mutations in a gene-specific manner, 
Artificial Transcription Factors (ATFs) have been explored (13). ATFs consist of a 
transcriptional regulatory domain coupled to a DNA binding domain, generally an 
engineered Zinc Finger Protein, which can be designed to target virtually any gene 
in the human genome (14, 15). Advantages of ATFs include the potency to repress 
undruggable targets, and activate silenced genes which will occur from the 
endogenous gene locus (allowing all splice variants to be expressed, in natural 
ratios). The therapeutic potential of ATFs in cancer has been demonstrated eg by 
the re-activation of TSG MASPIN in breast, lung and ovarian cancer (16, 17) or 
down-regulation of SOX2 (18), VEGF-A (19), ERBB2 (20) and ERBB3 (Holbro, Beerli, 
Maurer, Koziczak, Barbas, Hynes, 2003), leading to apoptosis and/or cell growth 
inhibition. 
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    For cervical cancer, the third most common malignancy among women 
worldwide, current screening programs rely on pap-smear assays which have poor 
sensitivity. As alternative to the pap-smear, our group and others reported several 
gene promoters that are specifically hypermethylated in cervical cancer and could 
thus serve as biomarkers for screening (21-24). The most potent 
hypermethylation marker we identified was C13ORF18, which was methylated in 
~70% of cervical cancer patients, compared to 3% in scrapings from healthy 
controls (24, 25). As promoter hypermethylation is often seen for TSGs, we 
hypothesized that this gene might exhibit tumor suppressive activities upon re-
expression. In this study, we therefore aimed to specifically re-express C13ORF18 
in cervical cancer cell lines using ATFs and study the effect of re-expression on in 
vitro cancer-related cell biological features.  
 
Materials and methods 
 
Cell culture 
Four cervical carcinoma cell lines (HeLa (cervical adenocarcinoma), SiHa (cervical 
squamous cell carcinoma), CaSki (epidermoid cervical carcinoma) and C33A 
(cervical epithelial carcinoma)), primary human dermal fibroblasts (adult) 
(ScienCell) and HEK293T cells (human embryonic kidney) were cultured in DMEM 
containing 10% FBS, 2mM L-glutamine and 50 µg/ml gentamycin. Cell lines were 
obtained from ATCC and authenticity of cervical cancer cell lines was verified by 
DNA short tandem repeat analysis (Baseclear). Treatment of cell lines with 5-aza-
dC (Sigma) (500 nM or 5 µM) and trichostatin A (TSA) (Sigma) (500 nM) was 
performed as described previously (26). ATF-transduced cells were treated for 2 
days with 5-aza-dC. Co-treatment of ATF with TSA was performed for 24 hours at 
day two after infection.  
 
Engineering and delivery of ATFs  
The promoter of C13ORF18 was analyzed using Ensemble and PubMed (NCBI-id: 
NM_025113) databases for transcription start sites (TSS) (situated 66 bp upstream 
of the initiator (Inr) sequence ‘TCA (G/T) T (T/C)’) and transcription factor binding 
sites (Figure 1a and 1b). The region flanking the main TSS (from -410 bps till + 610 
bps) was screened for engineering the zinc finger proteins (ZFPs) consisting of 6 
fingers fused together (6ZFP) to target 18 bps regions (www.zincfingertools.org) 
(27). ZFPs with predicted high affinity were selected and the uniqueness of the 
target sites was confirmed by a blast on NCBI. DS-DNA Oligos (Mr Gene, Bio-
Basics) for each 6ZFP flanked with the restriction site SfiI were subcloned into the 
pMX-IRES-GFP retroviral vector (16), which carries an HA-tag, a nuclear 
localization signal and either the gene activator VP64 or no effector domain (NoEf) 
(28). A previously reported EpCAM specific ZFP (15) was also cloned into the pMX-
IRES-GFP retroviral vector and used as irrelevant ATF. To produce retroviruses  
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pseudotyped with glycoprotein G from vesicular stomatitis virus (VSV-G), HEK293T 
packaging cells were transfected with pMX-IRES-GFP with or without VP64 insert 
along with the viral packaging plasmids pMDg/p and pMDg in a 3:2:1 ratio using 
the calcium phosphate method. pMDg/p and pMDg were a kind gift from dr. R. 
Mulligan (Harvard Medical School, Boston, MA, USA). Virus-containing 
supernatant was harvested at 24 and 48 h after transfection, cleared from cell 
debris by centrifugation, supplemented with 6 µg/ml polybrene (Sigma) and used 
to infect cervical cancer host cells. Efficient viral delivery was evaluated by the 
percentage of GFP-positive cells at 2 days after transduction using flow cytometry 
using a FACSCalibur (BD Biosciences).  
 
Quantitative real-time PCR 
Total RNA was extracted (RNeasy plus mini kit, Qiagen) from untreated, viral 
treated, or 5-aza-dC and TSA treated cells and 2.5 µg was used for reverse 
transcription. Subsequent real-time PCR reactions (ABIPrism 7900HT, Applied 
Biosystems) for the quantification of C13ORF18, GAPDH and VP64 activation 
domain were performed with 20 ng cDNA, Rox enzyme mix (Thermo Scientific) 
and gene specific primer/probes (Table 1) for 40 cycles. PCR efficiency of every 
primer/probe pair was determined by performing a standard curve. RNA samples 
prepared without reverse transcriptase were included to rule out cross reaction 
with DNA, Data were analyzed with SDS 2.1 RQ software (Applied Biosystems) and 
expression levels relative to GAPDH were determined with the formula 2-ΔCt. Fold 
increase in gene-expression compared to controls was calculated with the formula 
2-ΔΔCt. Samples for which no amplification could be detected were assigned a Ct 
value of the total number of PCR cycles. 
 
(Bisulfite) sequencing 
The methylation status of 65 CpGs in the C13ORF18 promoter was examined using 
bisulfite sequencing. For amplifying part of the C13ORF18 promoter, we used 
primers specific to the bisulfite modified promoter region of C13ORF18 (Figure 1, 
Table 1). Amplified PCR products were separated by electrophoresis and 
subsequently purified by gel extraction (Qiagen). The purified PCR products were 
cloned into the pCR 2.1-TOPO Vector (Invitrogen) and transformed into TOP10 
competent bacteria. Plasmids of positive recombinants were isolated (Qiagen) 
and subjected to sequencing (Baseclear) using M13 primers. Percentages of 
methylation for each clone were determined by dividing the amount of 
methylated CpGs by the total number of CpGs.  
       Sequencing of ATF target sites was performed using 1 primer pair spanning 
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Chromatin ImmunoPrecipitation (ChIP) 
Histone modifications associated with the C13ORF18 promoter (before and after 
ATF treatment) were determined by ChIP. In short, cells were fixed with 1% 
formaldehyde for 10 min and subsequently washed twice with PBS, lyzed and  
sonificated using a Bioruptor (High, 15 cycles of 30” on, 30” off, total time 15 min) 
(Diagnode). Sheared chromatin was cleared by centrifugation. Magnetic beads 
(Invitrogen) were pre-coated by adding 3 µg of antibodies (HA-tag (ab9110), H3-
core (ab1791), normal rabbit IgG (ab46540) (Abcam), acH3 (06-599), acH4 (06-
598), H3K9me3 (07-442) and H3K27me3 (07-449) (Millipore)) to 50 µl of magnetic 
beads, followed by 15 min incubation and a washing step. Sheared chromatin of 1 
million cells was added to the magnetic beads and incubated at a rotating 
platform at 4°C O/N. Next day, magnetic bead complexes were washed with PBS 
three times and the DNA was subsequently eluted from the beads. Elutes were 
supplemented RNAse (Roche) followed by O/N incubation at 67°C. Next day, DNA 
was purified by column purification (Qiagen) after a final incubation step at 45°C 
for 1 hour with Proteinase K (Roche). The recovered DNA was subsequently 
subjected to Quantitative real-time PCR using primers and probes specific for the 
C13ORF18 promoter (Figure 1, Table 1). Relative enrichment in the recovered 




Following treatment, cells were plated in 96 wells plates (1000 cells per well) and 
incubated for 5 days at 37°C. Every day, cell growth was measured using a 
thiazolyl blue tetrazolium blue (MTT) (Sigma) assay. MTT (5mg/ml) was added to 
wells followed by 3.5 hours of incubation at 37°C. Then, plates were centrifuged, 
medium was aspirated and MTT crystals were dissolved in DMSO. The absorbance 




Following treatment, cell were plated in 6-wells plates (800 cells per well). After 
two weeks, medium was aspirated and colonies were stained with Coomassie 
brilliant blue (Bio-Rad). The number of colonies was determined using phase-
contrast microscopy, only colonies with at least 50 cells were counted. 
 
Apoptosis assay  
Induction of apoptosis was quantified using a 1,1’,3,3,3’,3’-
Hexamethylindodicarbocyanine iodide (DilC) assay (Enzo Life Sciences). Following 
treatment, cells were trypsinized and incubated in culture medium supplemented 
with DilC (50 nM) for 15 min at 37°C. After washing with PBS, DilC signal was 
analyzed using FACS Calibur (BD Biosciences). The percentage of apoptotic cells  
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was determined as the number of viable cells with decreased DilC intensity, as 
reported before (29). As positive control, apoptosis was induced with Actinomycin 
D (ActD) at a final concentration of 20 µM and 40 µM. To inhibit apoptosis, cells 
were co-treated with ActD (20 µM) and Z-VAD-fmk (Z-VAD) (20 µM) or Caspase 8 
inhibitor (50 µM). 
 
Statistics 
Statistical significant differences were determined by the Student’s t-test. A p-
value of less than 0.05 was considered statistically significant with *p<0.05, 






Figure 1. Schematic representations of the promoter region of the C13ORF18 gene. The 
analyzed part of the promoter encompasses a region that stretches from -410 to +610 bp 
relative to the main TSS (+1). An additional putative TSS is shown (+265). (A) Core 
promoter elements and putative transcription factors binding sites (  AP-1R,  p53, 
 SP1 and  E2F  (MatInspector)) linked to C13ORF18 transcription. (B) CpGs are 
indicated as vertical bars. DNA methylation status of the CpGs was analyzed using bisulfite 
sequencing and MSP for the indicated areas. Association of histone modifications with the 
C13ORF18 gene were characterized for the ChIP region. (C) Target sequences of 1ab-VP64, 
2ab-VP64, 3ab-VP64, 4ab-VP64 and 5ab-VP64 are shown, as well their schematic locations 




C13ORF18 is epigenetically regulated in cervical cancer  
We determined C13ORF18 expression in a panel of well-established cervical 
cancer cell lines: HeLa, SiHa and CaSki cells show no or very low levels of 
C13ORF18 (Figure 2a), whereas C33A showed low expression levels of the gene. 
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C13ORF18 gene silencing in the three cell lines was associated with near complete 
promoter hypermethylation (HeLa 89±0.8%, SiHa 96±2.1%, CaSki 94±1.0%) (Figure 
2b), while the C13ORF18 gene was almost completely unmethylated in C33A cells 




Figure 2. The expression of C13ORF18 is associated with DNA methylation.  (A) 
Quantification of C13ORF18 mRNA in the panel of cell lines. (B) Analysis of the 
methylation status of 65 CpGs in the C13ORF18 promoter of HeLa, SiHa, CaSki and C33A 
cells. Each circle represents a single CpG and 3 clones per cell line were analyzed (65 CpGs 
per clone). Shown are the TSS ( ) and the ATF target sites covering this area ( ). (C) 
Relative C13ORF18 mRNA induction after treatment with 5-aza-dC (500 nM (+), 5 µM (++)) 
and TSA, normalized to untreated cells. Expression/induction levels were quantified with 
qRT-PCR and the bars represent the mean of at least three independent experiments ± 
SEM.  
 
      Treatment of HeLa, SiHa and CaSki with 5-aza-dC induced expression of 
C13ORF18 mRNA in a dose-dependent way (Figure 2c). Highest re-expression 
levels were obtained for high dose 5-aza-dC (5 µM) after co-treatment with the 
histone de-acetylase inhibitor TSA, (HeLa 34±7.2 fold, SiHa 51±11 fold, CaSki 
21±7.6). These findings confirm previous indications that DNA methylation and 
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C13ORF18 re-expression by ATFs 
Retroviral constructs containing VP64 were engineered to express the different 
ATFs (pMX-1ab-VP64, pMX-2ab-VP64, pMX-3ab-VP64, pMX-4ab-VP64 and pMX-
5ab-VP64). The zinc fingers contained 6 fingers and were constructed to target 
five 18 bp regions in the C13ORF18 promoter, surrounding the TSS (1ab, 2ab, 3ab, 
4ab, 5ab) (Figure 1c). The five ZF target sites were intact, as no DNA mutations 
were detected in neither of the cervical cancer cells (Supplementary Figures 1a 
(HeLa), 1b (CaSki) and 1c (C33A)). Efficient transcription of ATF mRNA was 
confirmed for all cell lines (Supplementary Figure 2a). GFP positivity ranged from 
60% for pMX-1ab-VP64 to 90% for pMX-5ab-VP64 (for C33A, Figure 3a).  
       First, we examined the ability of the 5 ATFs to upregulate endogenous 
C13ORF18 mRNA expression in the C13ORF18 low-expressing cell line C33A 
(Figure 3b). C13ORF18 was significantly up-regulated in this cell line by 3ab-VP64 
(43±6.2 fold (p<0.0001)), 4ab-VP64 (4.6±1.3 fold (p<0.05)) and 5ab-VP64 (28±5.4 
fold (p<0.0001)), whereas the controls (3ab-NoEf, 5ab-NoEf and the irrelevant 
ATF) did not show any effect on C13ORF18 mRNA levels. 1ab-VP64 and 2ab-VP64, 
although more efficiently expressed than 4ab-VP64, (Supplementary Figure 2a), 
failed to up-regulate C13ORF18 expression in C33A.  
In the hypermethylated CaSki cells (Figure 3c, filled bars), both 3ab-VP64 (44±6.5 
fold (p<0.001)) and 5ab-VP64 (29±5.2 fold (p<0.001)) were able to significantly re-
activate the C13ORF18 promoter. No re-expression was induced by 1ab-VP64, 
2ab-VP64 and 4ab-VP64 in CaSki cells. 
    Despite the lack of effect of 1ab-VP64 in CaSki and C33A, induction of 
C13ORF18 mRNA was most pronounced in HeLa cells by 1ab-VP64, with an 
induction level of 112±38.9 fold (p<0.05) (Figure 3c). Interestingly, the induced 
C13ORF18 expression in the methylated cell line HeLa by 1ab-VP64 was 3 fold 
higher than the endogenous expression of C13ORF18 in C33A cells (Figure 2a), 
which comprises an unmethylated promoter.  
As it has been shown that epigenetic drugs synergize with ATF treatment (30), we 
explored the possibility of ATF treatment in combination with epigenetic drugs to 
enhance or even induce the effects of the ATFs. In HeLa cells, co-treatment of 
ATFs with epigenetic drugs further increased ATF induced expression of C13ORF18 
mRNA (Figure 3d). Significant additive effects were reached with 3ab- VP64 (up to 
144±22 fold (p<0.001)) and 5ab-VP64 (up to 124±18 fold (p<0.001)) after co-
treatment with both 5-aza-dC (5 µM) and TSA. Interestingly, ATF 2ab-VP64, which 
had no effect by itself on gene activation in HeLa, consistently induced C13ORF18 
re-expression when co-treated with TSA. The same consistent effect was seen for 
1ab-VP64 +TSA, which resulted in the highest observed induction of C13ORF18 re-
expression in this study (339±106 fold), which is 9 fold higher than the 
endogenous expression of C13ORF18 in C33A cells. 
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Figure 3. C13ORF18 specific ATFs upregulate/induce expression in cervical cancer cell 
lines.  (A) Percentage of GFP positive cells after retroviral delivery of an empty vector 
(pMX empty), C13ORF18- targeting  ATFs (1ab-VP64, 2ab-VP64, 3ab-VP64, 4ab-VP64 and 
5ab-VP64), ZFPs without effector domain (3ab-NoEf and 5ab-NoEf) and an irrelevant ATF 
(EpCAM ATF) in C33A cells. (B) Relative upregulation of C13ORF18 mRNA after ATF 
treatment in C33A cells. (C) Relative induction of C13ORF18 mRNA after treatment with 
the different pMX constructs (1ab-VP64, 2ab-VP64, 3ab-VP64 and 5ab-VP64 and 3ab-
NoEf) in HeLa and CaSki cells. (D) Effect of co-treatment of ATFs with 5-aza-dC (5 µM) or 
TSA on induction of C13ORF18 mRNA in HeLa cells. Quantification of mRNA was 
performed using qRT-PCR and induction levels were normalized to untreated cells. Each 
bar represent the mean of at least three independent experiments (ATF-NoEf and 
irrelevant ATF two experiments) measured in triplicate ± SEM. 
 
   To detect association of ATFs with the C13ORF18 promoter, a ChIP for HA-tag 
was performed after ATF treatment alone (CaSki, Supplementary Figure 2b) or in 
combination with TSA (C33A, Supplementary Figure 2c). For CaSki, 3ab-VP64 
association with the C13ORF18 promoter was detectable in 1% of input DNA 
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observed in 2.5% of input DNA, which was increased by 2 fold when co-treated 
with TSA.     
 
ATF-induced gene expression affects epigenetic marks 
To determine whether the ATF-induced C13ORF18 gene re-expression was 
associated with DNA demethylation and/or histone modifications of its promoter, 
bisulfite sequencing and ChIP was performed. For HeLa, pMX-1ab-VP64-
transduced cells, which showed the strongest C13ORF18 re-expression (Figure 3c), 
showed partial demethylation mainly around the target site of ATF-1ab (+80 to 
+218), and around the TSS (-35 to +52) (Figure 4a left panel). Quantification of the 
methylated status of the total bisulfite sequencing region of the 5’ end of the 
C13ORF18 promoter (Figure 4a right panel) showed a significant decrease in 
methylation of 17±0.6% compared to untreated cells (p<0.001). Co-treatment of 
1ab-VP64 with TSA, which even better enhanced C13ORF18 re-expression (Figure 
3d), did not further increase DNA demethylation compared to 1ab-VP64 alone 
(1ab-VP64: -17±0.6%, 1ab-VP64 + TSA: -14±2.0%). Targeted DNA demethylation 
was also observed for CaSki after treatment with 3ab-VP64 at its target site (which 
overlaps the TSS) (untreated cells: 94±1.0%, 3ab-VP64: 88±1.5% p<0.01) (Figure 
4a right panel filled bars). 
    As DNA methylation is closely linked to histone modifications, ATF treatment 
might lead to a change in the pattern of histone modifications. We studied if 
forced C13ORF18 gene re-expression by ATFs indeed changed the histone state to 
a more active state. As HeLa cells treated with 1ab-VP64 did not yield sufficient 
surviving cells (see also Figure 5), C33A and CaSki cells were treated with 3ab-
VP64 and 3ab-NoEf to express C13ORF18. Figure 4b (left panel) shows that re-
activation of C13ORF18 in C33A did not influence the active histone marks H3Ac 
and H4Ac, but significant less trimethylation of H3K9 was observed (3ab-NoEf 
4.5±0.7, 3ab-VP64 1.9±0.8 (p<0.05)). For H3K27me3, the decrease by ATF-induced 
expression did not reach statistical significance (3ab-NoEf 9.3±1.4, 3ab-VP64 
6.0±2.4 (p=0.3)). For CaSki, significantly less trimethylation of H3K9me3 after 3ab-
VP64 treatment could be detected as well (3ab-NoEf 15±2.5, 3ab-VP64 3.3±0.3 
(p<0.01)) (Figure 4b right panel).  
 
C13ORF18 function as a tumor suppressor gene 
Next, we studied whether ATF-VP64-induced re-expression of C13ORF18 resulted 
in any functional effect on cell growth and apoptosis. In HeLa (Figure 5a), 
apoptosis was induced in 50±1.1% of the cells by 20 µM of ActD and in 97±2.3% of 
the cells by 40 µM ActD. The apoptotic induction was blocked with the pan-
caspase inhibitor Z-VAD and Caspase 8 inhibitor to 11±5.0% and 6.5±1.5% of the 
cells, respectively. In 1ab-VP64-transduced HeLa cells with the highest 
upregulation of C13ORF18 mRNA (Figure 3c), apoptosis was significantly increased 
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(7.1±0.6 fold (p<0.0001)) compared to cells transduced with an empty vector 




Figure 4. Changes in histone marks and DNA methylation after ATF induced re-
expression of C13ORF18. (A) DNA methylation status is shown for two subregions (from -
35 to +52 and from +80 to +218) flanking the 5’ promoter of the C13ORF18 promoter in 
untreated, ATF treated and ATF + TSA treated HeLa cells (right panel). Shown are the TSS   
( ) and the 1ab-VP64 target site  ( ). Each circle represents a single CpG and 5 clones 
per condition were analyzed. The right panel shows the quantification of the DNA 
methylation of all 65 CpGs in the sequenced C13ORF18 promoter region before and after 
ATF treatment in HeLa (ATF alone or in combination with TSA) and CaSki cells: each bar 
represents the mean percentage of DNA methylation of five individual clones ±S.D. (B) 
Quantitative ChIP for histone acetylation (H3Ac (and H4Ac)) and histone methylation 
(H3K9me3 (and H3K27me3)) after treatment with 3ab-NoEf or 3ab-VP64 in C33A cells (left 
panel) and CaSki cells (right panel). Values represent the mean of at least three 
independent experiments measured in triplicate ± SEM.  
 
VP64 could be decreased by apoptosis inhibitors (Figure 5b); 3.2±0.5 fold for Z-
VAD (p<0.001) and 2.8±0.4 fold for Caspase 8 inhibitor (p<0.001). Contrary, a 
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the histone de-acetylase inhibitor TSA (1ab-VP64 54±4.8, 1ab-VP64 + TSA 77±3.4% 
(p<0.01)), while TSA alone did not induce apoptosis in this dose (TSA: 2.5±2.5%). 
Co-treatment with 5-aza-dC did not further increase the apoptotic effect of 1ab-
VP64. The apoptotic effect of 1ab-VP64 is also reflected in the colony formation 
potential of the HeLa cells, as treatment with 1ab-VP64 strongly decreased the 
number of colonies compared to 1ab-NoEf, 2ab-VP64, 3ab-VP64 and 5ab-VP64 
(Figure 5c). Cell growth in HeLa was completely prevented after treatment with 
the most potent C13ORF18 inducing ATF (1ab-VP64) (Figure 5d) after 6 days of 
growth (p<0.001). The constructs with moderate (3ab-VP64, 5ab-VP64) or no 
C13ORF18 re-expression (2ab-VP64; 1ab-NoEf) induced far less effects on cell 
growth (2ab-VP64 -37%, 3ab-VP64 -31% and 5ab-VP64 -25%) compared to pMX 
empty (100%) and 3ab-NoEf (104%). For CaSki, the best C13ORF18 mRNA-inducing 
constructs (3ab-VP64) significantly decreased cell proliferation (-59±8.9% 
(p<0.05)) (Supplementary Figure 3a) and colony formation (-73±3.3% (p<0.05)) 
(Supplementary Figure 3b) compared to pMX empty. The same effects on cell 
growth and colony formation in this cell line were observed for 5ab-VP64 (-
43±19% and -52±9.3% (p<0.05) respectively) and not for 5ab-NoEf. 
     The ATFs did not induce apoptosis in normal healthy cells (primary human 
adult fibroblasts) (Supplementary Figure 3c). However, co-treatment of fibroblasts 
with 1ab-VP64 and TSA, but not 5-aza-dC, did result in a small, although significant 
induction of apoptosis (1ab-VP64 + TSA 5.8±0.4%, pMX empty 3.8±0.4% (p<0.05)). 
 
Discussion 
Based on its differential methylation profile in cancer versus normal tissues and its 
predicted function as a phosphatase inhibitor, C13ORF18 has been suggested to 
function as a TSG in cervical cancer (22, 24, 25). In the present study, we show 
that C13ORF18-directed ATFs are able to restore expression of C13ORF18 and that 
its re-expression is indeed associated with growth inhibition and apoptosis 
demonstrating its function as a tumor suppressor gene.  
       Few studies so far linked C13ORF18 to biological roles; C13ORF18 was linked 
to autophagy (31) and identified as a marker to distinguish JAK2V617F-negative 
thrombocythaemia patients (32), but provided only little mechanistic insights into 
how C13ORF18 might assert its tumor suppressive activities. In another study, 
C13ORF18 was associated with the cascade leading to cell senescence after down-
regulation of the human papillomavirus (HPV) E7 oncogene (33). It may well be 
that C13ORF18 silencing in cervical cancer is a consequence of introduction of 
HPV in cervical cells, which may facilitate in transforming normal cells into a 
malignant phenotype. This is also supported by the notion that the only 
C13ORF18-expressing cell line used in this study (C33A) is HPV negative. Re- 
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Figure 5. C13ORF18 targeting ATFs induce apoptosis and decrease cell growth. (A) 
Percentage of apoptotic cells after treatment with pMX empty and C13ORF18 directed 
ATFs in HeLa cells. In control cells, apoptosis was induced with Act-D alone or in 
combination with Z-VAD or Caspase 8 inhibitor (Casp.8 inh.). (B) Percentage of apoptotic 
cells after co-treatment of 1ab-VP64 with 5-aza-dC (500 nM (+), 5 µM (++)), TSA, Z-VAD or 
Casp.8 inh. in HeLa cells. Quantification of apoptotic cells was assessed with a DilC assay 
reflecting a decrease in mitochondrial membrane potential. All bars represent the mean of 
at least 3 independent experiments ± SEM. (C) Visualization of colony forming potential of 
HeLa cells of a representative Coomassie blue staining after treatment with C13ORF18 
specific ATFs or pMX empty. (D) Relative cell proliferation of HeLa cells after treatment 
with pMX empty, 1ab-VP64, 2ab-VP64, 3ab-VP64, 5ab-VP64, 1ab-NoEf and 3ab-NoEf 
normalized to day 1. Cell proliferation was assessed using a MTT assay and each data point 
represents the mean of in general three independent experiments measured in triplicate ± 
SEM. Significant growth differences between pMX empty and the ATFs were determined 
at day 6. 
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activation of C13ORF18 might therefore indeed induce anti-tumor effects as 
observed by us. Our results support the hypothesis that the methylation marker, 
C13ORF18, has TSG characteristics and may serve as a therapeutic target. 
Interestingly, the observed anti-tumor effects seem to be cancer-specific, as 
primary human fibroblasts cells are largely unaffected by ATF treatment in terms 
of apoptosis. Although co-treatment of ATFs with TSA induced a slight apoptotic 
response in fibroblasts, the apoptotic effect was much more pronounced in 
cervical cancer cells co-treated with TSA. 
   Epigenetically silenced genes are therapeutically exploited through re-
expression by epigenetic drugs (34, 35). Besides the use of epigenetic drugs in the 
treatment of patients with hematological malignancies, ongoing clinical trials for 
epigenetic drugs indicate beneficial effects for solid tumors as well (10). 
Impressive results were achieved for lung cancer patients with a combination of 
epigenetic drugs (10) and currently epigenetic drugs are in clinical trial for many 
cancers, including cervical cancer (36). However, the disadvantages of these drugs 
include their lack of target specificity: non-chromatin targets are also affected and 
although up-regulation is expected, many genes get down-regulated (37). 
Furthermore, many cancers are relatively resistant to epigenetic therapy and 
adverse effects have been described leading to early study termination as 
reported for an ovarian cancer study (38). The biggest problem with this study 
was that unwanted genes were also up-regulated, which made the outcome of 
the treatment unpredictable and variable between tumors.   
     In order to achieve gene-specific re-expression of TSGs, ATF technology is 
promising and induction of gene expression has been reported for several 
endogenous genes, like ERBB2 (39), VEGF-A (40) and Utrophin (41). Despite the 
repressive chromatin environment, ATFs can gain access and re-express 
epigenetically silenced genes (14), including the tumor suppressor gene MASPIN 
in breast (16) and lung cancer cell lines (17). Here, we extend these findings and 
show that ATFs can induce C13ORF18 gene expression even in the 
hypermethylated cell lines HeLa and CaSki. Variations were observed in the 
effectiveness of the ATFs between the cell lines, which could not be explained by 
genetic mutations in the ZF binding sites (Supplementary Figure 1). Also, 
differences in DNA methylation patterns do not underlie the differential effects 
observed, e.g. 1ab-VP64 effectively induced expression of C13ORF18 in HeLa 
(methylated), but not in C33A (unmethylated) or CaSki (methylated). 
Characteristics of the chromatin, such as DNA methylation or histone 
modifications, however, are known to affect functionality of ATFs and epigenetic 
drugs have been reported to synergize with ATFs to enhance the ATF-induced 
effects, as shown by us and others (Beltran, Sun, Lizardi, Blancafort, 2008). Apart 
from differential binding of ATFs in different cell lines, position effects (resulting in 
absence of transcriptional effects even though the ZF can access its target site) 
have been reported for effector domains, including VP64 (Lund, Blancafort, 
4 
 
Chapter 4  
76 
Popkov, Barbas, 2004). It may very well be that the enhanced effects of ATFs by 
epigenetic drugs are caused by increased binding of the ATF to its endogenous 
target sites as indicated by us here. Importantly, the ATF 2ab-VP64, which had no 
detectable re-expression activities in any cell line, was able to re-activate the 
C13ORF18 promoter in combination with TSA. Another mechanism by which 
epigenetic drugs might enhance ATF-induced effects is by protein acetylation. 
Acetylation of lysine residues within transcription factors is a mechanism by which 
cells can overcome gene repression (42). However, acetylation of the C-terminal 
zinc finger domain of the sequence-specific DNA-binding transcription factor YY1 
has been shown to result in decreased DNA-binding of YY1 (43). As our results 
show enhanced binding of ATFs after TSA treatment, increased acetylation of 
engineered ZFPs -if induced at all by TSA treatment- will most likely not affect 
binding negatively.  
               Affinity of ATFs to their target sites not only depends on the local 
structure of the chromatin, ATFs can have an impact on chromatin as well. As 
shown by us, specific re-expression of C13ORF18 by ATFs was associated with site-
specific promoter DNA demethylation. Previously, the demethylating effect of 
ATFs was also reported for the MASPIN ATFs (17). As a possible explanation, it was 
suggested that the demethylation is a result of a passive mechanism 
consequential to the recruitment of the RNA Pol II transcriptional complex to the 
MASPIN promoter. However, recent findings show that hypermethylated genes 
can be re-expressed to high levels by treatment with HDAC inhibitors, without 
affecting the DNA methylation status of the promoter (37). In line with this, we 
also show that loss of DNA methylation by the ATF is independent of the level of 
gene re-expression, as co-treatment with TSA greatly increased the level of re-
expression, but did not further increase the DNA demethylation status.  
      A direct relationship exists between the levels of DNA methylation and histone 
methylation and such crosstalk regulates chromatin structure (44). It is therefore 
likely that the ATF-induced DNA demethylation is associated with decreased 
histone methylation as indeed found here and also recently observed in an 
artificial stable ATF-system for p16 (45). 
      As some epigenetic changes might be inherited during cell divisions, ATF-
mediated demethylation may therefore even result in more permanent gene re-
expression. Some evidence for this notion is provided by the heritable regulation 
of AP3 by ATFs in plants over two subsequent generations (46). Also the MASPIN 
ATFs induced prolonged re-expression of MASPIN for four cell generations in 
absence of the MASPIN ATF mRNA using Dox-inducible constructs (47). However, 
in the MASPIN study the ATF protein levels were not evaluated. For the long term, 
the induced heritability effects by ATFs are still unknown and might not even be 
expected as no enzymatic activity is targeted. A recent improvement to the field is 
the induction of sustained silencing of MASPIN and the oncogene SOX2 in breast 
cancer (18): ZFPs linked to a DNA methyltransferase induced methylation at the 
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target site, enabling stable phenotypic reprogramming of the cancer cell. Such 
epigenetic editing approaches could also be designed by targeting activating 
histone modifiers or DNA demethylases to induce more sustained re-expression of 
genes, as reviewed recently (48)     In this study, we found that ATF-induced levels 
of C13ORF18 repressed tumor growth. This is the first study to demonstrate 
tumor suppressive activity of a biomarker gene with unknown function, and 
shows that hypermethylated marker genes can be attractive targets for 
therapeutic strategies, although the use of ATFs in a clinical setting still faces 
some challenges (49), novel delivery systems are being developed allowing for 
safer administration and higher efficacy (50, 51). Together, the specificity, 
biological effect, synergy with epigenetic drugs and “inheritability” effect of ATFs 
might offer great therapeutic potential for the treatment of cancer. As the 
amount of epimutations in cancer exceeds the number of gene mutations, ATFs 
provide promising tools to validate hypermethylated marker genes as therapeutic 
targets.   
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Supplementary Figure 1 (A). Sequences of five 18 bp regions (1ab, 2ab, 3ab, 4ab, 5ab) in 
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Supplementary Figure 2. (A) Quantification of ATF mRNA in HeLa, CaSki and C33A after 
retroviral delivery of C13ORF18 targeting ATFs (1ab-VP64, 2ab-VP64, 3ab-VP64, 4ab-VP64 
and 5ab-VP64). Expression levels were quantified with qRT-PCR and the bars represent the 
mean of in general three independent experiments measured in triplicate ± SEM. (B) ATF 
association with the C13ORF18 promoter in CaSki cells after treatment with 3ab-VP64 as 
assessed by ChIP using an anti-HA-tag antibody. (C) ATF association with the C13ORF18 
promoter in C33a cells after 5ab-VP64 treatment alone or in combination with TSA. IgG 
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Supplementary Figure 3. (A) Relative cell proliferation of CaSki cells after treatment with 
pMX empty, 3ab-VP64, 5ab-VP64 and 5ab-NoEf normalized to day 1. Cell proliferation was 
assessed using a MTT assay and each data point represents the mean of at least two 
independent experiments measured in triplicate. Significant growth differences between 
pMX empty and the ATFs were determined at day 5. (B) Relative number of colonies after 
retroviral delivery of pMX empty, 3ab-VP64, 5ab-VP64 and 5ab-NoEf in CaSki cells. Each 
data point represents the mean of three independent experiments measured in 
triplicates. (C) Percentage of apoptotic cells after treatment with pMX empty and 
C13ORF18 directed ATFs in primary human fibroblasts, also after co-treatment of 1ab-
vp64 with 5-aza-dC (5μM) or TSA. Quantification of apoptotic cells was assessed with a 
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